Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo
Proceedings of the National Academy of Sciences · 09.06.2026 · 123 (23)
DOI: 10.1073/pnas.2606213123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 05.06.2026. Verfasst von Anne Rietz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Repressor Proteins, Tumor Suppressor Protein p53, Human papillomavirus 16. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mary Kay Ash Foundation (MKF), HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR), NCATS NIH HHS.
Abstract (Originalsprache)
High-risk human papillomaviruses (HPVs) promote malignant progression through sustained expression of the viral oncoprotein E6, which drives degradation of the tumor suppressor p53 and creates an oncogenic dependency in HPV-positive cancers. Here, we identify a genotype-defined therapeutic vulnerability by selectively and irreversibly inactivating HPV-16 E6 through covalent targeting a cysteine proximal to its E6AP-binding interface. Pharmacologic inhibition of E6 restored p53 protein stability and transcriptional activity in HPV-16–positive cancer cells, inducing apoptosis and senescence while sparing HPV-negative epithelial cells. A CRISPR-engineered E6 cysteine-to-serine knock-in abolished compound activity in vitro and in vivo, establishing on-target mechanism. Transcriptomic profiling confirmed activation of p53-dependent tumor suppressor programs following E6 inactivation. In xenograft models of cervical and oropharyngeal cancer, irreversible inhibition of E6 suppressed growth of established tumors with minimal toxicity and no evidence of acquired resistance. These findings support covalent inactivation of HPV-16 E6 by a small molecule as a therapeutic strategy for HPV-associated malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Indiana University School of Medicine, Indianapolis, IN 46202.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202.
- Kovina Therapeutics Inc., Indianapolis, IN 46202.
ORCID-Profile: Lokesh Kumari, Stephane Pelletier, Zhijian Lu, Elliot J Androphy
Förderung
- Mary Kay Ash Foundation (MKF)
- HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR)
- NCATS NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- NCI NIH HHS
- HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases (DMID)
- Kovina Therapeutics Inc.
Zitieren
APA
Rietz, A., Kumari, L., Koirala, A., Pelletier, S., Lu, Z., & Androphy, E. J. (2026). Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo. Proceedings of the National Academy of Sciences, 123(23). https://doi.org/10.1073/pnas.2606213123
Vancouver
Rietz A, Kumari L, Koirala A, Pelletier S, Lu Z, Androphy EJ. Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo. Proceedings of the National Academy of Sciences. 2026;123(23). doi:10.1073/pnas.2606213123
BibTeX
@article{Rietz2026,
author = {Rietz, Anne and Kumari, Lokesh and Koirala, Ankeeta and Pelletier, Stephane and Lu, Zhijian and Androphy, Elliot J},
title = {Covalent inhibitors of human papillomavirus type 16 E6 protein restore p53 function and suppress growth of HPV-driven tumors in vivo},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {23},
doi = {10.1073/pnas.2606213123}
}
EUVIMED